Plain-English translation of NCT06542159 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a newer form of focused radiation therapy called online adaptive stereotactic body radiotherapy (SBRT) for people with early-stage lung cancer or a small number of lung tumors that have spread. The key innovation is that this treatment uses real-time imaging during each radiation session to adjust the beam precisely, which may allow doctors to eliminate the extra safety margins typically added around tumors—potentially delivering more targeted treatment with fewer side effects.
Standard radiation therapy adds safety margins around tumors to account for small movements and uncertainties during treatment. This trial exists to see whether advanced imaging technology can make radiation therapy precise enough to eliminate those extra margins, potentially improving how well the treatment works while reducing harm to surrounding healthy lung tissue.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to either the new adaptive radiation therapy approach or standard radiation therapy. Both groups receive the same total radiation dose delivered over 3–4 daily sessions. Before each treatment session, you will have imaging scans taken to help guide the therapy. The adaptive therapy group will receive additional specialized imaging (called 4DCT and FBCT) to allow real-time adjustment of the radiation beam. After treatment ends, you will have regular follow-up appointments to monitor how well the treatment worked and to watch for any side effects.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China